source
- Arrowhead’s plozasiran shows favorable safety in severe hypertriglyceridemia late-stage trialsArrowhead presented late-stage data for its RNA interference therapy plozasiran, marketed as Redemplo, in severe hypertriglyceridemia at the European Society of Cardiology 2026 meeting in Munich.…
- Electra Therapeutics files for Nasdaq IPO to fund phase 2/3 immunology and cancer programsElectra Therapeutics, based in South San Francisco, announced it has filed a registration statement to list its shares on the Nasdaq Global Select Market under the ticker ETRA. The company says th…